Drug profile · INN
zilucoplan sodium
ZILBRYSQ
zilucoplan sodium (ZILBRYSQ) is a complement c5 binding agent. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — zilucoplan sodium
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 9
- Programs
- 3
- Data quality
- 0.84
Quick answer
zilucoplan sodium (ZILBRYSQ) is a complement c5 binding agent. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Complement C5 binding agent
Primary target: Complement C5
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11965040
Modulation of complement activity
granted -
US 11752190
Modulators of complement activity
granted -
US 11535650
Modulation of complement activity
granted -
US 11014965
Modulation of complement activity
granted -
US 10835574
Modulators of complement activity
granted -
US 10562934
Modulation of complement activity
granted -
US 10435438
Modulation of complement activity
granted -
US 10208089
Modulation of complement activity
granted -
US 10106579
Modulation of complement activity
granted
Frequently asked questions
What is zilucoplan sodium?
zilucoplan sodium (ZILBRYSQ) is a complement c5 binding agent. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for zilucoplan sodium?
ZILBRYSQ is a marketed brand name for zilucoplan sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zilucoplan sodium?
zilucoplan sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.